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Biologic agents have dramatically shifted the treatment paradigm for rheumatic disease. Use of these agents can decrease
disease burden, allow the patient to be weaned from corticosteroids, and reduce the likelihood of relapse. Eye disease associated
with rheumatic conditions may present with a wide range of signs and symptoms. This coexisting pathology should not be
overlooked and should be considered a reason for initiation or continuation of biologic therapy. Additionally, many of the
ocular manifestations of rheumatic disease respond preferentially to speciﬁc targeting molecules. This paper summarizes the
available studies on the use, eﬃcacy, and safety of biologic agents in the treatment of ocular manifestations of rheumatic
disease.
1.Introduction
Eye disease associated with rheumatic conditions may
present with a wide range of signs and symptoms. The
treating physician must be careful not to overlook ocular
manifestations, as they can be quite subtle. Dry eye syn-
drome, acute and chronic anterior uveitis, panuveitis or
vitritis, scleritis, keratitis, retinal vasculitis, and ischemic
optic neuropathy represent ocular disorders frequently asso-
ciated with rheumatic diseases. In patients presenting with
nonspeciﬁc signs and symptoms, ocular ﬁndings may be the
only clue to the ﬁnal diagnosis. Alternatively, in patients
withlong-standing rheumaticdisease,ophthalmicﬂaresmay
suggest further deterioration or relapse.
The mainstay of management of inﬂammatory ocular
conditions has been topical agents with occasional oral
corticosteroid use. However, for some conditions these ther-
apies are often inadequate. Biologic therapies (Table 1)h a v e
demonstrated eﬃcacy in the control of many of the primary
manifestationsofrheumaticdisease.Theirtargeteduseinthe
ocular manifestations of rheumatic disease has not been as
extensively studied. This paper seeks to compile the available
reports on the use, eﬃcacy, and safety of biologic agents in
the treatment of ocular symptoms of rheumatic disease.
2. Adamantiades-Behc ¸et’sDisease
Ocular symptoms occur in 43–72% of Adamantiades-
Behc ¸et’s disease (ABD) patients and aﬀect males more com-
monly than females. The classic appearance is that of an
anterior uveitis with a sterile hypopyon; however, presenta-
tions more often feature a posterior or diﬀuse uveitis with
accompanying retinal vasculitis [1].
ABD is an aggressive, sight-threatening disease that
requires immunosuppressive therapy to avoid vision loss.
TNF-α antagonists are the preferred ﬁrst line agent for
treatment of ABD. They have proven successful in control-
ling symptoms, reducing ocular relapses, and signiﬁcantly
decreasing the daily dose of corticosteroids [2, 3]. Inﬂiximab
has emerged as the foremost agent with several prospective
studies demonstrating remission of anterior and posterior
segment inﬂammation, resolution of macular edema, and
successful control of uveitis refractory to previous therapy
[4, 5]. Among the anti-TNF-α agents, inﬂiximab has been2 International Journal of Rheumatology
Table 1: Biologic agents.
Biologic agent Trade name Mechanism of action
TNF-α blockers
Inﬂiximab Remicade Chimeric monoclonal antibody
against TNF-α
Etanercept Enbrel TNF receptor-IgG fusion protein
Adalimumab Humira Human monoclonal antibody
against TNF-α
Certolizumab pegol Cimzia
PEGylated Fab of a humanized
TNF inhibitor monoclonal
antibody
Golimumab Simponi Humanized monoclonal
antibody against TNF-α
Lymphocyte inhibitors
Rituximab Rituxan Chimeric monoclonal antibody
against CD20
Abatacept Orencia Selective inhibitor of T-cell
costimulation
Anti-interleukin antibodies
Anakinra Kineret IL-1 receptor antagonist
Daclizumab Zenapax Humanized monoclonal
antibody to IL-2 receptor
Tocilizumab Actemra Humanized monoclonal
antibody to IL-6R
Basiliximab Simulect Chimeric monoclonal antibody
to the CD25
Speciﬁc receptor antibodies
Efalizumab Raptiva CD11a, a pan-leukocyte surface
marker, inhibitor
Alefacept Amevive CD2 inhibitor
Alemtuzumab Campath-1H CD52, a pan-lymphocyte
antigen, antagonist
Anti-VEGF-A antibodies
Ranibizumab Lucentis Monoclonal antibody fragment
(Fab) targeting VEGF-A
Bevacizumab Avastin Monoclonal antibody targeting
VEGF-A
shown to achieve the best control of ocular signs and symp-
toms [1, 6].
While not as extensively studied, several reports have
suggested etanercept and adalimumab are eﬀective in con-
trolling ABD disease severity [7, 8] .T r e a t m e n tw i t he t a n e r -
cept achieves a greater response in ocular manifestations of
ABD over other complications such as oral ulcers, arthritis,
and skin lesions [9]. Adalimumab may induce and maintain
sustained remission of refractory ocular inﬂammation in
about 90% of patients [10].
Among the other biologic agents, rituximab has shown
success in retinal vasculitis associated with ABD [11]. A case
report describing the eﬀective management of ABD with
anakinra did not address ocular symptoms [12]. The ability
of therapy targeting interleukin activity to reduce disease
burden suggests IL-1β is a mediator of inﬂammation in ABD
and may eﬀectively treat its ocular manifestations.
3.Rheumatoid Arthritis
Rheumatoidarthritis(RA)givesrisetosigniﬁcanteyedisease
in 15–30% of aﬀected patients. Characteristic presentations
include keratoconjunctivitis sicca (KCS), stromal keratitis,
sclerosing keratitis, scleritis, and episcleritis. KCS is by far
themostcommonocularmanifestation(11.6%),followedby
episcleritis and scleritis [13].
Dry eyes can be signiﬁcantly disabling and diﬃcult
to treat. Aggressive lubrication, punctal plugs, autologous
serum drops, prednisolone drops, and topical cyclosporine
make up the ophthalmologist’s armamentarium. This local-
ized approach satisfactorily controls most patients; however,
systemic steroids and increased methotrexate are occasion-
ally necessary. Although not sight threatening, symptoms
can exert an increasing burden as the disease progresses
or increases in severity. KCS patients have various degreesInternational Journal of Rheumatology 3
of health-related quality of life impairment [14]. Although
unconventional, initiation of inﬂiximab in otherwise qui-
escent RA has successfully controlled KCS symptoms [15].
Evidence suggests that the indirect costs of KCS actually may
outweigh the expense of biologic treatment [16].
Reinforcing the importance of TNF-α in the control of
corneal inﬂammation, the TNF-α antagonists, inﬂiximab,
adalimumab, and etanercept have been shown to be eﬀective
therapiesforRA-associatedkeratitis.Theyhaveshowndiﬀer-
ing levels of eﬃcacy [17–19]. Inﬂiximab has been shown to
be the most eﬀective agent to control RA-associated keratitis
[20, 21]. Rituximab has been used successfully in the treat-
ment of severe peripheral ulcerative keratitis (PUK) demon-
strating prior resistance to anti-TNF agents [22]. However, a
case of bilateral PUK following treatment with rituximab has
been reported. Causation was not established [23].
Necrotizing scleritis is the most destructive form of scle-
ritis and has considerable ocular morbidity. In patients with
RA, it is associated with a high mortality, especially when
not treated with immunosuppressants. Anti-TNF-α agents
have the most evidence supporting their use and eﬃcacy
in scleritis. Certolizumab pegol has been shown to control
scleritis in a patient with RA who had failed other TNF-α
antagonists [24].
Inﬂammation control in the eyes of RA patients remains
a challenge. Head to head comparison trials of the many
biologics have not been completed. A large review of several
individual studies indicated that TNF-α antagonists (cer-
tolizumab, adalimumab, inﬂiximab, etanercept), the B-cell
inhibitor (rituximab), and the IL-6 blocker (tocilizumab) are
superiortoT-cellcostimulationinhibitor(abatacept)andthe
IL-1 blocker (anakinra). However, none of the comparisons
between these biologics reached statistical signiﬁcance [25].
4.JuvenileIdiopathic Arthritis
Uveitis occurs in 10%–15% of patients with juvenile idio-
pathic arthritis (JIA) and represents the primary cause of
uveitis in childhood. Contrary to the red painful eye seen in
adultswithuveitis;theinﬂammationseeninchildrenisoften
asymptomatic and bilateral,withan indolent chronic course.
Severe vision loss, even blindness, occurs in an unacceptably
highpercentageofpatientswithone-quarterofchildrenwith
JIA becoming blind in one eye [26].
Topical steroids are the ﬁrst line of therapy, but only
around 40% of patients respond to such treatment. The
associatedrisksofincreasedintraocularpressureandcataract
are particularly unappealing in a pediatric population. An
investigation into the eﬀectiveness of the three most popular
anti-TNF-α agents, etanercept, inﬂiximab, and adalimumab,
found inﬂiximab to be more eﬀective than etanercept.
No statistically signiﬁcant conclusion was drawn regarding
adalimumab [27]. Inﬂiximab, however, was found to have
ah i g hr a t eo fs i d ee ﬀects in a prospective study [28]. The
preferred anti-TNF-α agent is adalimumab, which is more
eﬀective against uveitis than etanercept and better tolerated
by children [29].
Use of biologic agents not targeting TNF-α has only
recently been published. Rituximab has reported eﬃcacy
in patients refractory to treatment with TNF-α antagonists
[30]. Preliminary studies of high-dose intravenous adminis-
tration of IL-2 antagonist, daclizumab demonstrate a reduc-
tion in active inﬂammation in JIA-associated anterior uveitis
[31].Inaprospectivestudyofabataceptincasesrefractoryto
anti-TNF-α treatment, all seven children exhibited decreased
anterior segment inﬂammation. However, only one demon-
stratedcompleteresolutionwiththistreatment[32].Ahead-
to-head comparison of these newer agents has not been
performed.
5.Sjogren’sSyndrome
KCS, or severe dry eye, is the hallmark of Sjogren’s syndrome
(SS) and indicates an autoimmune attack on the lacrimal
gland. Therapeutic options for the debilitating xeroph-
thalmia are currently limited to symptomatic relief with
aggressive artiﬁcial lubrication, autologous serum eye drops,
topical cyclosporine, topical corticosteroids, and punctal
occlusion.
Understanding the inﬂammatory cascade involved in
SS suggests elevated levels of proinﬂammatory cytokines
(e.g., IL-1α,I L - 1 β,I L - 6 ,T N F α) and immunoactivators
(e.g., ICAM-1, CD40, CD40 ligand) play a role the ocular
symptoms [33]. Newer treatment strategies are targeting
these pathways as therapeutic options. Preliminary studies
of the anti-TNF-α agents were promising; however, a large
randomized trial failed to demonstrate a diﬀerence in
response between placebo and an inﬂiximab-treated group
[34]. Similarly, etanercept was also no more eﬀective than
placebo in a 12-week study [35].
While a recent double-blind, randomized, placebo-
controlled trial indicated that rituximab is eﬀective and
safe in the treatment of patients with SS, ocular signs
and symptoms were not among the measures demonstrat-
ing improvement with treatment [36] .Ac a s er e p o r td i d
report improvement in subjective and objective measures of
xerophthalmia in 2 patients treated with rituximab [37].
6.SeronegativeSpondyloarthropathy
The seronegative spondyloarthropathies, ankylosing spon-
dylitis (AS), psoriatic arthritis (PsA), inﬂammatory bowel
disease (IBD), and reactive arthritis (ReA) represent a group
of diseases that share clinical, genetic, and pathological
characteristics. They share an association with HLA-B27, an
absence of positive rheumatoid factor (negative serostatus),
and extra-articular features, such as involvement of eyes,
skin, and genitourinary tract.
Anterior uveitis reportedly occurs in up to 30% of
patients with AS. There is now accumulating evidence that
targeted anti-TNF-α therapy is highly eﬀective in spon-
dyloarthritis [38]. Patients taking anti-TNF-α agents exhib-
ited signiﬁcantly reduced rates of recurrence of anterior
uveitis in the major trials, with stronger protection aﬀorded
by inﬂiximab and adalimumab [39, 40]. Other biologics
have not shown as much promise; abatacept failed to show
improvement in any outcome measures in one prospective
study [41].4 International Journal of Rheumatology
TheclassictriadofReAincludesarthritis,nongonococcal
urethritis, and conjunctivitis. However, ocular manifes-
tations may also include acute anterior uveitis. Current
opinion is that because TNF-α drives the pathogenesis of
reactive arthritis and suggests TNF-α antagonists will be
eﬃcacious therapeutic tools. Like AS, deﬁnitive studies are
lackingbutisolatedcasereportssupporttheuseofanti-TNF-
α agents [42, 43].
Biologic treatment of the uveitis associated with PsA,
liketheotherseronegativespondyloarthropathies, centerson
the anti-TNF-α therapies [44]. Evidence suggests inﬂiximab
provides the greatest response among the anti-TNF-α agents
[45, 46].
Inﬂammatory bowel disease (IBD), like the other spon-
dyloarthropathies, can be associated with an acute anterior
uveitis. It also can present with a keratitis or scleritis.
Successful control of the ocular inﬂammation has been seen
in IBD patients using TNF-α antagonists [47]. Of the TNF-
α inhibiting therapies, etanercept is ineﬀective in controlling
boththesystemicsymptomsofIBDandtheassociateduveitis
[48].
7. RelapsingPolychondritis
Fifty-nine percent of patients with relapsing polychondritis
(RP) have ocular components of their disease. The most
common manifestation is scleritis, seen in 41% of patients;
uveitis is seen in one-quarter of patients; conjunctivitis,
episcleritis, keratitis, and retinal vasculitis are seen less fre-
quently [49]. Immunosuppressive chemotherapy is usually
required to successfully treat the ocular manifestations of RP,
especially nodular and necrotizing scleritis [50]. Inﬂiximab
was shown to diminish ocular manifestations [51].
8.SystemicVasculiticDisease
Giant cell arteritis (GCA) can cause an incredibly rapid total
or near total loss of vision. Without prompt recognition and
initiation of high-dose intravenous steroids, bilateral vision
loss may result in up to 50% of individuals. Maintenance
therapy with biologic agents is an attractive theory, as it
would allow avoidance of chronic steroids and the associated
morbidity. Studies of TNF-α antagonists have mixed results.
Inﬂiximab was not shown to be eﬀective in a prospective
randomized trial [52]. However, a case of reported steroid-
resistant GCA was treated successfully with adalimumab
[53]. Rituximab was also eﬀective in reducing inﬂammatory
markers in a patient with GCA refractory to treatment with
corticosteroids [54].
Ocular manifestations are very common in Wegener’s
granulomatosis (WG), aﬀecting approximately half of
patients. Scleritis, keratitis, orbital disease, and less com-
monly retinovasculitis or uveitis are all potential manifesta-
tions of WG [55]. The other ANCA-associated vasculitides,
microscopic polyangiitis, and Churg-Strauss present much
less frequently with ophthalmic complications. Reversal of
vision loss was seen in a case of severe posterior scleritis in
WG treated with inﬂiximab [56]. Rituximab has emerged
as an eﬀective tool in treating ocular manifestations of
WG [57, 58]. Recent evidence suggests it is equivalent
to cyclophosphamide for the induction of remission, with
particular eﬃcacy at inducing remission in patients with
relapsing disease [59]. It was shown to be superior to
inﬂiximab by a small prospective study [60].
9. Anterior Uveitis Induced by Anti-TNF Agents
As discussed above, extensive evidence supports the eﬃcacy
of TNF-α antagonists in the treatment of uveitis associated
withrheumatologicdisease.Paradoxically,useoftheseagents
has been implicated to cause uveitis. Several anecdotal case
reports suggested an association between use of these agents
and development of uveitis [61]. Subsequently, a review of
medication adverse event registries not only conﬁrmed this
observation but also suggested etanercept caused a greater
number of reported uveitis cases compared to inﬂiximab
and adalimumab [62]. A retrospective review reported a fre-
quencyof1caseper100patient-yearforpatientstreatedwith
aT N F - α antagonist for seronegative spondylopathy [63].
10. Conclusion
The last decade has seen a dramatic increase in the number
and nature of biologic agents. We continue to expand
our knowledge of rheumatologic disease and the role of
the inﬂammatory cascade in the ocular manifestations of
those diseases. Systemically, administered small molecular
antibodies and antagonists have become valuable tools in the
treatment of refractory ophthalmic symptoms of rheumatic
disease. In certain cases, these agents can even be considered
primary therapeutic options.
Recently, two humanized monoclonal antibodies tar-
geting vascular endothelial growth factor-A (VEGF-A),
ranibizumab (Lucentis) and bevacizumab (Avastin) have
revolutionized the treatment of eye diseases such as age-
related macular degeneration. These agents are delivered via
an intraocular injection and are eﬀective and well tolerated
[64]. Preliminary safety studies to evaluate toxicity of intrav-
itreal injection of TNFα inhibitors have been performed in
rabbitswith experimental uveitis, with promising results[65,
66]. Future treatment of ocular manifestations of rheumatic
disease will certainly build upon the documented eﬃcacy
of biologic agents and the ability to locally inject these
antibodies and antagonists.
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